OMER
OMEROS CORP
$11.60
-3.01%
$865.6M
No data for this timeframe.
Vol
Market Cap$865.6M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (73%)
Inst. Holders7 funds
Inst. Value$99.9M
Inst. Activity1 buys / 4 sells
Reddit Sentiment70° Bullish
SEC Reports2
Recent Activity
May 13, 2026
SEC
Omeros reported Q1 2026 results with first-ever YARTEMLEA commercial sales of $9.9M net, GAAP net income of $56.1M (vs a
8-K — Impact 6/10
Apr 21, 2026
SEC
Omeros reported a massive earnings beat for Q4 2025, driven by a $237.6M gain from the zaltenibart sale to Novo Nordisk
8-K — Impact 9/10
Feb 18, 2026
Insider
Demopulos Gregory A MD sold 400,000 shares
Chairman, CEO & President @ $10.27 ($4.1M)
Feb 18, 2026
Insider
Demopulos Gregory A MD sold 357,678 shares
Chairman, CEO & President @ $11.93 ($4.3M)
Feb 18, 2026
Insider
Demopulos Gregory A MD sold 400,000 shares
Chairman, CEO & President @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
524,757 shares ($9.0M)
Inst.
MORGAN STANLEY — NEAR_EXIT
386,152 shares ($6.6M)
May 19, 2026
short_volume
Short Volume: OMER — 67.0% short (0.3M / 0.5M)
Short: 343,078 | Exempt: 0 | TRF Vol: 512,032 | Short Ratio: 67.0% | Off-exchange volume (dark pool
Price Targets
$33.50
+188.8% upside
Strong Buy
Current $11.60
Low $27.00
Median $33.50
High $40.00
2 analysts
$27.00
$40.00
Analyst Ratings
3Strong Buy
5Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Jan 27, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Jan 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.09 ▲ +122.2% | $-0.27 — $0.80 | 116% YoY | 3 |
| Next Q | $-0.20 ▲ +44.6% | $-0.32 — $-0.05 | 39% YoY | 3 |
| Current FY | $0.42 ▲ +127.5% | $-0.13 — $0.89 | -80% YoY | 3 |
| Next FY | $0.54 ▼ -60.8% | $-0.38 — $1.68 | 28% YoY | 3 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $68.9M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $10.2M | NEW |
| TWO SIGMA INVESTMENTS, LP | $9.0M | TRIM |
| MORGAN STANLEY | $6.6M | NEAR_EXIT |
| WELLS FARGO & COMPANY/MN | $2.8M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 18, 2026 | Demopulos Gregory | M | $4.1M |
| Feb 18, 2026 | Demopulos Gregory | F | $4.3M |
| Feb 18, 2026 | Demopulos Gregory | M | $0.00 |
Reddit Sentiment
70°▲
Bullish
Bearish
Neutral
Bullish
7 institutional holders with $99.9M total value (5,815,602 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, TWO. Net selling activity: 4 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,013,315 | $68.9M | 69.0% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 593,222 | $10.2M | 10.2% | NEW |
| 3 | TWO SIGMA INVESTMENTS, LP | 524,757 | $9.0M | 9.0% | TRIM -43.8% |
| 4 | MORGAN STANLEY | 386,152 | $6.6M | 6.6% | NEAR_EXIT -80.6% |
| 5 | WELLS FARGO & COMPANY/MN | 165,280 | $2.8M | 2.8% | DOUBLED +164.9% |
| 6 | BANK OF AMERICA CORP /DE/ | 114,808 | $2.0M | 2.0% | TRIM -58.3% |
| 7 | FMR LLC | 18,068 | $310.3K | 0.3% | ADD +37.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | TRIM | 933,314 | 524,757 | -43.8% | $9.0M | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 1,989,734 | 386,152 | -80.6% | $6.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 275,418 | 114,808 | -58.3% | $2.0M | 2025-Q4 |
| FMR LLC | ADD | 13,190 | 18,068 | +37.0% | $310.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 344,500 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,355,559 | 1,989,734 | +46.8% | $8.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 670,219 | 933,314 | +39.3% | $3.8M | 2025-Q3 |
| MORGAN STANLEY | ADD | 760,360 | 1,355,559 | +78.3% | $4.1M | 2025-Q2 |
| UBS Group AG | ADD | 660,657 | 868,500 | +31.5% | $2.6M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 105,639 | 670,219 | +534.4% | $2.0M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 382,700 | — | $1.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 112,200 | 250,959 | +123.7% | $752.9K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 46,206 | 122,387 | +164.9% | $367.2K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 333,882 | 760,360 | +127.7% | $6.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 330,625 | 415,926 | +25.8% | $3.4M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 162,991 | 105,639 | -35.2% | $868.4K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 33,148 | 46,206 | +39.4% | $379.8K | 2025-Q1 |
| FMR LLC | TRIM | 19,368 | 13,340 | -31.1% | $109.7K | 2025-Q1 |
| UBS Group AG | ADD | 450,074 | 849,187 | +88.7% | $8.4M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 214,712 | 330,625 | +54.0% | $3.3M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 485,035 | — | $1.9M | 2024-Q3 |
| MORGAN STANLEY | ADD | 197,351 | 297,926 | +51.0% | $1.2M | 2024-Q3 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | Demopulos Gregory A MD | Chairman, CEO & President | M | 400,000 | $10.27 | $4.1M |
| Feb 18, 2026 | Demopulos Gregory A MD | Chairman, CEO & President | F | 357,678 | $11.93 | $4.3M |
| Feb 18, 2026 | Demopulos Gregory A MD | Chairman, CEO & President | M | 400,000 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 7.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (73% buy). Based on 11 analysts: 3 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$33.50 mean target
+188.8% upside
Strong Buy (2.00)
$27.00 Low
$40.00 High
| Metric | Value |
|---|---|
| Current Price | $11.60 |
| Target Low | $27.00 |
| Target Mean | $33.50 |
| Target Median | $33.50 |
| Target High | $40.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.09 | $-0.27 | $0.80 | 116.3% | +122.2% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.20 | $-0.32 | $-0.05 | 38.5% | +44.6% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$0.42 | $-0.13 | $0.89 | -79.8% | +127.5% | — | $0.1B | 0.0% | 3 |
| Next FY 2027-12-31 |
$0.54 | $-0.38 | $1.68 | 27.6% | -60.8% | 0↑ 1↓ | $0.2B | 136.2% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.087 | |
| 7d ago | $-0.235 | +0.322 |
| 30d ago | $-0.390 | +0.477 |
| 60d ago | $-0.610 | +0.697 |
| 90d ago | $-0.610 | +0.697 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 27, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 24, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 1, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Feb 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Jan 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
70°
Bullish
Bearish
Neutral
Bullish
6 mentions
4 bullish
0 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
OMER: A Mid-Size Biotech Company
▲ 1
💬 0
⚡ 0.5
OMER: A Biotech on the Rise
▲ 1
💬 0
⚡ 0.5
OMER: A Biotech on the Rise
▲ 1
💬 1
⚡ 0.5
May 19, 2026
short_volume
Short Volume: OMER — 67.0% short (0.3M / 0.5M)
Short: 343,078 | Exempt: 0 | TRF Vol: 512,032 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: OMER — 81.2% short (0.6M / 0.8M)
Short: 644,909 | Exempt: 42,638 | TRF Vol: 793,757 | Short Ratio: 81.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: OMER — 75.0% short (1.0M / 1.3M)
Short: 984,684 | Exempt: 58,752 | TRF Vol: 1,312,696 | Short Ratio: 75.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: OMER — 77.6% short (1.2M / 1.5M)
Short: 1,176,891 | Exempt: 84,954 | TRF Vol: 1,516,582 | Short Ratio: 77.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
OMER Q1 2026 Earnings Scheduled — 2026-05-13
May 13, 2026
short_volume
Short Volume: OMER — 74.4% short (0.6M / 0.8M)
Short: 600,975 | Exempt: 1,372 | TRF Vol: 807,862 | Short Ratio: 74.4% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings_calendar
OMER Q1 2026 Earnings Scheduled — 2026-05-12
Apr 30, 2026
short_interest
FTD: OMER — 81,853 shares ($1.2M) failed to deliver
Settlement: 20260430, Price: $14.56, FTD Value: $1,191,779.68, OMEROS CORPORATION COM STK
Apr 28, 2026
short_volume
Short Volume: OMER — 57.1% short (0.4M / 0.7M)
Short: 411,650 | Exempt: 1,683 | TRF Vol: 721,308 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_interest
FTD: OMER — 83,249 shares ($1.1M) failed to deliver
Settlement: 20260427, Price: $13.53, FTD Value: $1,126,358.97, OMEROS CORPORATION COM STK
Apr 24, 2026
short_volume
Short Volume: OMER — 69.4% short (0.4M / 0.6M)
Short: 446,536 | Exempt: 3,041 | TRF Vol: 643,713 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
Phase Phase 2 — TERMINATED
Mar 31, 2026
short_interest
FTD: OMER — 140,721 shares ($1.4M) failed to deliver
Settlement: 20260331, Price: $9.81, FTD Value: $1,380,473.01, OMEROS CORPORATION COM STK
Mar 31, 2026
earnings_calendar
OMER Q4 2025 Earnings After Market Close — 2026-03-31
Mar 30, 2026
earnings_calendar
OMER Q4 2025 Earnings After Market Close — 2026-03-30
Mar 18, 2026
short_interest
FTD: OMER — 66,390 shares ($0.7M) failed to deliver
Settlement: 20260318, Price: $11.27, FTD Value: $748,215.3, OMEROS CORPORATION COM STK